Paclitaxel and Carboplatin With or Without Epirubicin in Treating Patients With Stage IIB, Stage III, or Stage IV Invasive Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer
A Randomized Trial of Paclitaxel/Epirubicin/Carboplatin Combination (TEC) Versus Paclitaxel/Carboplatin (TC) in the Treatment of Women With Advanced Ovarian Cancer
Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Listed as NCT00004934, this PHASE3 trial focuses on Fallopian Tube Cancer and Ovarian Cancer and remains completed. Sponsored by European Organisation for Research and Treatment of Cancer - EORTC, it has been updated 7 times since 1999, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Oct 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Oct 2021 [monthly]
Completed PHASE3
▶ Show 2 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE3
First recorded
Aug 1999
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- European Organisation for Research and Treatment of Cancer - EORTC
- NCIC Clinical Trials Group
- Nordic Society of Gynaecological Oncology - Clinical Trials Unit
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aalborg, Denmark , Barcelona, Spain , Brescia, Italy , Calgary, Canada , Coimbra, Portugal , Duluth, United States , Enschede, Netherlands , Fleurimont, Canada , Hamilton, Canada , Jerusalem, Israel and 8 more locations